Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

MLA

Rana, Zohaib, et al. “Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer.” Pharmaceuticals (Basel, Switzerland), vol. 14, no. 10, Oct. 2021. EBSCOhost, https://doi.org/10.3390/ph14101020.

APA

Rana, Z., Diermeier, S., Walsh, F. P., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel, Switzerland), 14(10). https://doi.org/10.3390/ph14101020

Chicago

Rana, Zohaib, Sarah Diermeier, Fearghal P Walsh, Muhammad Hanif, Christian G Hartinger, and Rhonda J Rosengren. 2021. “Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer.” Pharmaceuticals (Basel, Switzerland) 14 (10). doi:10.3390/ph14101020.